CAR T-cell therapy basics. ... proliferation, safety, and efficacy. 1. Key bioanalysis components. ... For more thorough profiling, a combination of assay platforms can be used.

These secondary signals are necessary for T cell activation and require the engagement of proteins on T cells, such as CD28, and other proteins on APCs, including the CD80/CD86 complex. Signal 2 ...

KLF7 is known to promote T cell proliferation. When analyzing samples from LBCL patients treated with CAR-T therapy, they found that the CAR-T cells with higher levels of KLF7 were associated with ...

The results were promising as a proof-of-concept in shielding specific tissues from harm. Synthetic suppressor T cells successfully curbed CAR T cell proliferation in the dual-antigen tumor, ...

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting breakthrough against hematologic cancers. 6 We and others have shown the clinical safety and efficacy of allogeneic CD7 CAR T ...

Orca-T, an investigational allogeneic T-cell immunotherapy, improved cGVHD-free survival compared with allo-HSCT in patients with acute leukemia or MDS in the phase 3 Precision-T trial (NCT05316701).

The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind ...

More information: Mats Jerkeman et al, Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden, Leukemia (2025).